Indications for: LOPRESSOR HCT
Titrate individual components. Give in 1–2 divided doses. Max 50mg/day HCTZ.
LOPRESSOR HCT Contraindications:
Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt heart failure. Cardiogenic shock. Sick-sinus syndrome. Severe peripheral circulatory disorders. Anuria. Sulfonamide allergy.
Avoid abrupt discontinuation in ischemic heart disease.
LOPRESSOR HCT Warnings/Precautions:
CHF. Ischemic heart disease. Bronchospastic disease, COPD. Renal or hepatic dysfunction. Gout. Diabetes. Postsympathectomy. Hyperthyroidism. Surgery. SLE. Avoid abrupt cessation. Monitor electrolytes. Pregnancy (Cat.C). Nursing mothers: not recommended.
LOPRESSOR HCT Classification:
Cardioselective beta-blocker + diuretic.
LOPRESSOR HCT Interactions:
Potentiated by alcohol, CNS depressants, other antihypertensives. Bradycardia with catecholamine-depleting drugs. Metoprolol potentiated by felodipine. Increased toxicity of calcium channel blockers, lidocaine, diazoxide, digitalis, lithium. Antagonized by NSAIDs, barbiturates, rifampin. Amphotericin B, ACTH, corticosteroids increase hypokalemia risk. Adjust antidiabetic medication. May antagonize epinephrine. May interfere with parathyroid, glaucoma screening tests.
Fatigue, bronchospasm, dizziness, drowsiness, headache, fluid or electrolyte imbalance, bradycardia, depression, dyspnea, GI upset, blurred vision, tinnitus, earache, impotence, myalgia, cold extremities, CHF, heart block; HCTZ: increased risk for non-melanoma skin cancer.